Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Biofilms growth & development MeSH
- Gram-Negative Bacterial Infections epidemiology microbiology prevention & control MeSH
- Immunocompromised Host MeSH
- Cross Infection epidemiology microbiology prevention & control MeSH
- Infection Control methods MeSH
- Humans MeSH
- Drug Resistance, Multiple, Bacterial MeSH
- Hospitals MeSH
- Stenotrophomonas maltophilia isolation & purification physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
Stenotrophomonas maltophilia (Sm) plays an important role as an opportunistic pathogen in immunocompromised individuals. The growing detection rates of this bacterium in hospitalized patients are associated with the invasiveness of therapeutic and diagnostic procedures and the selection pressure of antibiotic therapy. A broad range of infections that can be caused by Sm is frequently bound to biofilm. The high level of intrinsic resistance to many unrelated antibiotics and increasing acquired resistance to the drug of choice, trimethoprim-sulfamethoxazole pose a threat for the near future when our treatment options may become depleted. Prevention of colonization and infection consists in consequent implementation of the rules governing nosocomial infection control, rational use of antibiotics including the optimization of selection and testing of antimicrobial agents suitable for the treatment of stenotrophomonad infections.
See more in PubMed
J Antimicrob Chemother. 2000 Dec;46(6):879-84 PubMed
Diagn Microbiol Infect Dis. 2009 Mar;63(3):330-3 PubMed
Clin Microbiol Rev. 2008 Jul;21(3):449-65 PubMed
Infect Control Hosp Epidemiol. 2007 Jul;28(7):825-31 PubMed
J Infect. 2003 Nov;47(4):273-95 PubMed
J Antimicrob Chemother. 2008 Aug;62(2):256-78 PubMed
Am J Respir Crit Care Med. 2002 Aug 1;166(3):356-61 PubMed
Clin Microbiol Rev. 1998 Jan;11(1):57-80 PubMed
Future Microbiol. 2009 Nov;4(9):1103-9 PubMed
J Antimicrob Chemother. 2007 Mar;59(3):583-5 PubMed
J Clin Microbiol. 2007 Feb;45(2):529-35 PubMed
Clin Microbiol Infect. 2006 Oct;12(10):986-91 PubMed
Clin Infect Dis. 2007 Dec 15;45(12):1602-9 PubMed
N Engl J Med. 2002 Oct 3;347(14):1110-1 PubMed
Pediatr Pulmonol. 2000 Jul;30(1):10-5 PubMed
Clin Microbiol Infect. 2006 Apr;12(4):315-21 PubMed
Ann Hematol. 2003 Jul;82(7):452-4 PubMed
Eur J Clin Microbiol Infect Dis. 2009 Jul;28(7):719-30 PubMed
Angiology. 2002 Jan-Feb;53(1):49-55 PubMed
J Hosp Infect. 1995 Jun;30 Suppl:453-64 PubMed
Future Microbiol. 2009 Aug;4(6):655-60 PubMed
J Antimicrob Chemother. 2003 Apr;51(4):803-11 PubMed
Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):229-37 PubMed
Infect Immun. 2007 Apr;75(4):1698-703 PubMed
J Antimicrob Chemother. 2002 Feb;49(2):387-9 PubMed
J Bacteriol. 2007 Jul;189(13):4964-8 PubMed
Emerg Infect Dis. 2007 Apr;13(4):559-65 PubMed
J Biol Chem. 2002 Mar 29;277(13):11042-9 PubMed
J Clin Microbiol. 2001 Jan;39(1):139-45 PubMed
Trends Microbiol. 2006 Jun;14(6):277-86 PubMed
Nat Rev Microbiol. 2005 Jan;3(1):36-46 PubMed
J Antimicrob Chemother. 2008 Nov;62(5):889-94 PubMed
Lancet Infect Dis. 2009 May;9(5):312-23 PubMed
Bone grafts as vancomycin carriers in local therapy of resistant infections
Establishment of an arabinose-inducible system in Stenotrophomonas maltophilia
